Biodesix (BDSX) to Release Quarterly Earnings on Tuesday

Biodesix (NASDAQ:BDSX) is expected to be posting its Q1 2025 quarterly earnings results after the market closes on Tuesday, May 13th. Analysts expect Biodesix to post earnings of ($0.08) per share and revenue of $19.50 million for the quarter. Biodesix has set its FY 2025 guidance at EPS.

Biodesix (NASDAQ:BDSX) last posted its earnings results on Monday, March 3rd. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. The company had revenue of $20.43 million for the quarter, compared to analyst estimates of $19.92 million. Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%. On average, analysts expect Biodesix to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Biodesix Stock Performance

BDSX stock opened at $0.38 on Friday. Biodesix has a one year low of $0.34 and a one year high of $2.04. The firm has a market cap of $55.46 million, a price-to-earnings ratio of -0.97 and a beta of 1.18. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.40 and a current ratio of 3.40. The firm has a 50-day simple moving average of $0.63 and a two-hundred day simple moving average of $1.03.

Insider Buying and Selling

In other Biodesix news, CEO Scott Hutton sold 83,660 shares of the firm’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total value of $76,967.20. Following the completion of the transaction, the chief executive officer now owns 701,947 shares of the company’s stock, valued at approximately $645,791.24. This trade represents a 10.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders sold 128,702 shares of company stock worth $118,406 in the last three months. Corporate insiders own 69.20% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on BDSX shares. Canaccord Genuity Group decreased their target price on shares of Biodesix from $3.50 to $2.50 and set a “buy” rating for the company in a research report on Tuesday, April 29th. William Blair reiterated an “outperform” rating on shares of Biodesix in a report on Tuesday, March 4th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $2.83.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.